Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00759824
Recruitment Status : Completed
First Posted : September 25, 2008
Last Update Posted : February 12, 2015
Information provided by (Responsible Party):
European Lung Cancer Working Party

Brief Summary:
The primary aim of this study is to determine if the addition of valproic acid to a combination of adriamycin, cyclophosphamide and vindesine could increase progression-free survival in patients relapsing after first-line chemotherapy including platinum derivatives, cisplatin or carboplatin, and etoposide.

Condition or disease Intervention/treatment Phase
Small Cell Lung Carcinoma Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
Study Start Date : September 2008
Actual Primary Completion Date : December 2013
Actual Study Completion Date : June 2014

Arm Intervention/treatment
Experimental: 1
Chemotherapy regimen (adriamycin, cyclophosphamide, vindesine) plus valproic acid
Drug: Adriamycin, cyclophosphamide, vindesine, valproic acid
Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally

Primary Outcome Measures :
  1. Six-months progression-free survival [ Time Frame: The period between the day of registration and the date of first progression ]

Secondary Outcome Measures :
  1. Survival [ Time Frame: Survival will be dated from the date of registration ]
  2. Response rate [ Time Frame: Every three cycles of chemotherapy ]
  3. Toxicity [ Time Frame: After each course of chemotherapy and at the end of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological diagnosis of small-cell lung cancer (SCLC)
  • SCLC refractory to prior chemotherapy regimen including platinum derivatives (cisplatin or carboplatin) and etoposide, either primary refractory (immediate progression or recurrence less than 3 months after the end of previous chemotherapy) or secondary refractory (sensitive patients to platinum plus etoposide in first-line, progressing or recurring less than 3 months after reintroduction of the same chemotherapy).
  • At least one evaluable or measurable lesion
  • Availability for participating in the detailed follow-up of the protocol
  • Signed informed consent.

Exclusion Criteria:

  • Patient who were previously treated with anthracyclin or vinca-alcaloid derivatives or cyclophosphamide
  • Performance status < 60 on the Karnofsky scale
  • A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or of the bladder or cured malignant tumour (more than 5-year disease free interval)
  • A history of prior HIV infection
  • Polynuclear cells < 2,000/mm³
  • Platelet cells < 100,000/mm³
  • Abnormal coagulation tests (aPTT, PTT, prothrombin time) and/or decreased fibrinogen
  • Serum bilirubin >1.5 mg/100 ml
  • Transaminases more than twice the normal range
  • Serum creatinine > 1.5 mg/100 ml
  • Recent myocardial infarction (less than 3 months prior to date of diagnosis)
  • Congestive cardiac failure (ejection fraction of the left ventricle < 50%) or uncontrolled cardiac arrhythmia
  • Uncontrolled infectious disease
  • Active epilepsy needing a specific treatment
  • Concomitant treatment with IMAO, carbamazepine, mefloquine, phenobarbital, primidone, phenytoïn, lamotrigine, zidovudine
  • Pregnancy or refusal to use active contraception
  • A known allergy to valproic acid and/or doxorubicin, cyclophosphamide, vindesine
  • Serious medical or psychological factors which may prevent adherence to the treatment schedule.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00759824

Layout table for location information
Department of Intensive Care Unit and Thoracic Oncology Institut Jules Bordet
Brussels, Belgium, 1000
Department of Pneumology CHU Charleroi
Charleroi, Belgium, 6000
Department of Pneumology Hôpital Saint-Joseph
Gilly, Belgium, 6060
Hôpital Ambroise Paré
Mons, Belgium, 7000
Department of Pneumology Centre Hospitalier de Mouscron
Mouscron, Belgium, 7700
Sponsors and Collaborators
European Lung Cancer Working Party
Layout table for investigator information
Study Chair: Thierry Berghmans, MD European Lung Cancer Working Party
Layout table for additonal information
Responsible Party: European Lung Cancer Working Party Identifier: NCT00759824    
Other Study ID Numbers: 01081
First Posted: September 25, 2008    Key Record Dates
Last Update Posted: February 12, 2015
Last Verified: February 2015
Keywords provided by European Lung Cancer Working Party:
Small cell lung carcinoma
Valproic acid
Second-line chemotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Small Cell Lung Carcinoma
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Liposomal doxorubicin
Valproic Acid
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
GABA Agents